Ocular Therapeutix (NASDAQ:OCUL – Get Free Report)‘s stock had its “outperform” rating restated by equities researchers at Robert W. Baird in a report issued on Thursday, Benzinga reports. They currently have a $18.00 target price on the biopharmaceutical company’s stock. Robert W. Baird’s target price would indicate a potential upside of 390.46% from the stock’s […]
EcoR1 Capital LLC boosted its position in shares of Zymeworks Inc. (NYSE:ZYME – Free Report) by 33.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 10,087,473 shares of the company’s stock after purchasing an additional 2,518,900 shares during the quarter. Zymeworks […]
Ironwood Investment Management LLC decreased its position in Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) by 3.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 63,976 shares of the biopharmaceutical company’s stock after selling 1,991 shares during the quarter. […]
Commodore Capital LP acquired a new stake in Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 2,824,029 shares of the company’s stock, valued at approximately $21,914,000. Vera Therapeutics comprises about 3.3% of Commodore Capital LP’s investment portfolio, […]
Atom Investors LP increased its position in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 75.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,224 shares of the biopharmaceutical company’s stock after buying an additional 17,293 shares during the period. […]